Di Marzo Vincenzo, Bifulco Maurizio, De Petrocellis Luciano
Endocannabinoid Research Group, Institute of Biomolecular Chemistry, National Research Council, Via Campi Flegrei 34, Comprensorio Olivetti, 80078 Pozzuoli, Napoli, Italy.
Nat Rev Drug Discov. 2004 Sep;3(9):771-84. doi: 10.1038/nrd1495.
The term 'endocannabinoid' - originally coined in the mid-1990s after the discovery of membrane receptors for the psychoactive principle in Cannabis, Delta9-tetrahydrocannabinol and their endogenous ligands - now indicates a whole signalling system that comprises cannabinoid receptors, endogenous ligands and enzymes for ligand biosynthesis and inactivation. This system seems to be involved in an ever-increasing number of pathological conditions. With novel products already being aimed at the pharmaceutical market little more than a decade since the discovery of cannabinoid receptors, the endocannabinoid system seems to hold even more promise for the future development of therapeutic drugs. We explore the conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come.
“内源性大麻素”一词最初是在20世纪90年代中期创造的，当时发现了大麻中精神活性成分Δ9-四氢大麻酚的膜受体及其内源性配体。现在，它指的是一个完整的信号系统，包括大麻素受体、内源性配体以及用于配体生物合成和失活的酶。该系统似乎与越来越多的病理状况有关。自发现大麻素受体以来，仅仅十多年的时间里就已经有新型产品瞄准了制药市场，内源性大麻素系统似乎在治疗药物的未来发展中更具前景。我们探讨了在未来几年中实现靶向内源性大麻素系统潜力的条件。
